Announcements - OBI Pharma 台灣浩鼎

2020.Dec.30

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (Announcement of base day and trading counterparty)

2020.Dec.25

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by National Medical Products Administration (NMPA) to proceed Phase III human clinical study

2020.Dec.14

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

2020.Dec.04

OBI licensed the Intellectual Property Right of Global Aesthetic Medicine to a designated company

2020.Nov.27

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)

2020.Nov.23

OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424

2020.Nov.06

Announcement of 2020 Q3 financial reports submitted to the board of directors

2020.Oct.15

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (the agreement of share exchange and cooperation signed, and trading counterparts designated)

2020.Oct.06

OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA

2020.Sep.28

OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.

News

Latest News

Events

Latest events